Pulmatrix Granted $5.7 Million from DARPA

Pulmatrix, a clinical-stage biotechnology company, has raised $5.7 million in a grant from the Defense Advanced Research Projects Agency, a unit of the Department of Defense. Lexington-Mass.-based Pulmatrix develops therapies aimed at preventing and treating respiratory diseases, including those caused by weaponized or engineered pathogens.

North AmericaUSBriefs